Metformin and ‘Anti‑Aging’: Promising Mechanisms but Mixed Clinical Evidence — What Recent Trials Tell Us
Posted inClinical Updates Family Medicine & Nutrition Internal Medicine news Specialties

Metformin and ‘Anti‑Aging’: Promising Mechanisms but Mixed Clinical Evidence — What Recent Trials Tell Us

Recent randomized and mechanistic studies provide a nuanced view: metformin shows plausible anti‑aging mechanisms and microbiome‑linked cognitive associations, but randomized trials report no clear anti‑cancer or anti‑senescence effects in humans to date.
Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy
Posted inCardiology Clinical Updates news Specialties

Decoding High‑Risk Enrollment in TWILIGHT: How Risk Feature Burden Shapes Ischemic and Bleeding Outcomes and the Consistent Benefit of Ticagrelor Monotherapy

Posthoc analysis of TWILIGHT shows that ischemic risk rises with the number of high‑risk features, bleeding does not, and ticagrelor monotherapy after 3 months reduces bleeding versus ticagrelor plus aspirin without increasing ischemic events across risk strata.
Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers
Posted inCardiology Clinical Updates Diabetes & Endocrinology news Psychiatry Specialties

Simvastatin Added to Escitalopram in Obese Patients With Major Depression: A Rigorous RCT Shows No Antidepressant Benefit Despite Improved Cardiometabolic Markers

A multicenter double-blind RCT (n=160) found that 12 weeks of simvastatin (40 mg) added to escitalopram did not improve depressive symptoms versus placebo, although LDL, total cholesterol, and CRP were reduced.
Therapist-Guided Internet CBT Cuts Bulimia Episodes: A Japanese Randomized Trial with Promising Clinical Implications
Posted inClinical Updates Gastroenterology news Psychiatry Specialties

Therapist-Guided Internet CBT Cuts Bulimia Episodes: A Japanese Randomized Trial with Promising Clinical Implications

A multicenter randomized trial in Japan found that a 12-week therapist-guided internet-based CBT program significantly reduced weekly bingeing and compensatory episodes in women with bulimia nervosa versus usual care (adjusted mean difference 9.84 episodes; Cohen d 0.73).
Blackcurrant Anthocyanins Improve Post‑prandial Vascular Function and Platelet Reactivity — Acute RCT Insights and Clinical Implications
Posted inClinical Updates news

Blackcurrant Anthocyanins Improve Post‑prandial Vascular Function and Platelet Reactivity — Acute RCT Insights and Clinical Implications

A randomized, double‑blind crossover trial found that a single 200‑mL anthocyanin‑rich blackcurrant beverage (711 mg anthocyanins) attenuated the adverse postprandial effects of a high‑fat meal on flow‑mediated dilation, platelet aggregation, and IL‑8 in healthy adults; effects were linked to specific phenolic metabolites.
Blackcurrant Anthocyanins Improve Postprandial Vascular Function and Platelet Reactivity: Acute Crossover Trial Highlights Metabolites Linked to Benefit
Posted inCardiology Clinical Updates Family Medicine & Nutrition news Specialties

Blackcurrant Anthocyanins Improve Postprandial Vascular Function and Platelet Reactivity: Acute Crossover Trial Highlights Metabolites Linked to Benefit

In a randomized, double‑blind crossover trial, a 200 mL anthocyanin‑rich blackcurrant beverage (≈711 mg anthocyanins) taken with a high‑fat meal improved flow‑mediated dilation and reduced agonist‑induced platelet aggregation and IL‑8 over 6 hours in healthy middle‑aged adults; specific circulating phenolic metabolites correlated with the responses.
Urolithin A for Muscle Health: A 4‑Month Randomized Trial Shows Improved Lower‑Limb Strength, Endurance Signals, and Mitochondrial Biomarkers
Posted inClinical Updates Family Medicine & Nutrition Internal Medicine news Specialties

Urolithin A for Muscle Health: A 4‑Month Randomized Trial Shows Improved Lower‑Limb Strength, Endurance Signals, and Mitochondrial Biomarkers

In a randomized, double‑blind 4‑month trial of middle‑aged overweight adults, oral urolithin A improved hamstring strength (~10–12%), increased peak VO2 and 6‑minute walk distance (clinically meaningful at 33 m for 1,000 mg), altered mitochondrial proteomic signatures, and reduced inflammation without major safety signals.
Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice
Posted inClinical Updates Family Medicine & Nutrition Neurology news Specialties

Medium‑Chain Triglyceride–Supplemented Ketogenic Diet in Parkinson’s Disease: A Small Randomized Feasibility Trial and What It Means for Clinical Practice

A randomized, double‑blind pilot tested an MCT‑supplemented ketogenic diet (MCT‑KD) in 16 people with moderate Parkinson’s disease. The diet was feasible and acceptable, induced nutritional ketosis by day 4, produced metabolic benefits and nonmotor symptom improvement, but did not change a primary mobility endpoint (TUG) over three weeks.
Posted inClinical Updates Family Medicine & Nutrition Neurology news Pediatrics Specialties

Ketogenic Diet vs Further Antiseizure Medication in Infants with Drug-Resistant Epilepsy: What the KIWE Trial Adds to Clinical Practice

The KIWE randomised trial (Lancet Neurol 2023) found no superiority of a classic ketogenic diet over an additional antiseizure medication for seizure frequency in infants (1–24 months) with drug‑resistant epilepsy; tolerability and safety profiles were similar, supporting the diet as a viable treatment option.